Abstract
MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies. However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372 expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues compared to the corresponding non-neoplastic brain tissues (P<0.001). In addition, the high miR-372 expression was significantly associated with the advanced pathological grade (P=0.008) and the low Karnofsky performance score (KPS) of glioma patients (P=0.01). Moreover, the overall survival of patients with high miR-372 expression was dramatically shorter than those with low miR-372 expression (P<0.001). Furthermore, multivariate Cox regression analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P=0.008). More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression group than for low miR-372 expression group (P<0.001), but no significant difference was found for patients with low pathological grades (P=0.08). Taken together, these data offer the convincing evidence for the first time that miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological grades.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1707761328850011
Highlights
Human gliomas are a heterogeneous group of primary intracranial tumors for both children and adults [1]
Results miR-372 upregulation in human glioma tissues MiR-372 expression was detected in 128 pairs of glioma and adjacent non-neoplastic brain tissues normalized to RNU6B
Subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grade (Grade III~IV) was significantly worse for high miR-372 expression group than for low miR-372 expression group (P
Summary
Human gliomas are a heterogeneous group of primary intracranial tumors for both children and adults [1]. According to the World Health Organization (WHO) classification which is based on histomorphological criteria, human gliomas includes well-differentiated low grade astrocytomas [World Health Organization (WHO) grade I~II], anaplastic astrocytomas (WHO grade III). MiRNAs play important roles in a wide variety of physiological and pathological processes involved in tumorigenesis and tumor progression. Depending on their target genes, miRNAs can function either as oncogenes or tumor suppressors. Its roles in gliomas have not been elucidated To address this problem, miR-372 expression in human gliomas and nonneoplastic brain tissues was measured by real-time quantitative RT-PCR assay. The association of miR-372 with clinicopathological factors or prognosis of glioma patients was statistically analyzed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
